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http://dx.doi.org/10.1016/j.jmii.2013Background: Chronic kidney disease (CKD) is a serious medical problem and public health issue
in Taiwan. Gastrointestinal symptoms frequently occur in patients with CKD, and proton pump
inhibitors (PPIs) have therapeutic indications for gastrointestinal disorders involving excessive
acid production. However, PPIs may also increase the risk of developing pneumonia through
acute and irreversible gastric acid suppression. This study aimed to characterize differences
in the risk of pneumonia in patients with CKD who use PPIs.
Methods: This population-based caseecontrol cohort study in Taiwan collected data from the
Taiwan Health Insurance Research Database. Cases studied consisted of all patients in the
database with an initial diagnosis of CKD during the 5-year period from 1997 to 2002. Eachfectious Diseases, Department of Medicine, Taipei Veterans General Hospital, Number 201, Section 2,
v.tw (C.-P. Fung).
to this study.
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Pneumonia risk with PPI in CKD patients 391patient with CKD who used PPIs during this 5-year period was tracked to identify the occur-
rence of any type of pneumonia. We estimated the adjusted hazard ratios (HRs) and 95% con-
fidence interval (95% CI) by using multiple logistic regression analysis.
Results: The adjusted HR of the risk of pneumonia for patients with CKD using PPIs was 2.21
(95% CIZ 1.59e3.07, p < 0.001). The risk of pneumonia was found to be positively associated
with administration of PPIs. We observed a greater risk of pneumonia in patients with CKD us-
ing PPIs than in patients not using PPIs.
Conclusion: Results of this study suggest that use of PPIs in CKD patients may be associated
with increasing the risk of pneumonia. Physicians should exercise caution while prescribing
PPIs for patients with CKD.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Proton pump inhibitors (PPIs) are drugs that have been
widely used for treating gastroesophageal reflux disease
(GERD), acute peptic ulcer, and other acid-peptic-related
diseases, for more than 20 years.1 A lack of gastric acid in
the stomach will reduce indigestion, pain, and heartburn
and aid in the healing of peptic ulcers. However, a related
concern is the risk of respiratory tract infection resulting
from profound acid inhibition due to the use of PPIs. Some
earlier studies have shown that treatment with PPIs may be
associated with increased risk of community-acquired
pneumonia.2e4 However, several other studies did not
support this finding.5e7 Consequently, this result has been
under debate for many years, without a consensus.
Chronic kidney disease (CKD) is a major public health
problem worldwide and especially so in Taiwan, where the
national prevalence of CKD was 11.9% with an increasing
incidence and prevalence of end-stage renal disease (ESRD)
requiring dialysis.8,9 Patients with CKD have a high inci-
dence of gastrointestinal disorders such as GERD and peptic
ulcers.10,11 PPIs are prescribed for most of these patients to
treat gastrointestinal symptoms. An overuse of PPIs in pa-
tients with CKD could produce adverse effects. Currently,
no study exists that investigates the risk of pneumonia in
patients with CKD who have received PPI therapy. We
studied the outpatient and inpatient claims data in the
cohort database of the Longitudinal Health Insurance
Database (LHID) 2005, a nationwide population-based
dataset that provided an excellent resource for evaluating
the risk of pneumonia among patients with CKD.
This study aimed to investigate the risk that patients with
CKD receiving PPI therapy could develop pneumonia. It also
aimed to characterize differences in the rate of occurrence
of pneumonia associated with different types of PPIs.Patients and methods
Data sources
In this study, data were collected from LHID 2005 released
by the Taiwan National Health Research Institutes (NHRI) in
2007. This sample population accounted for 5% of all
enrollees in the National Health Insurance (NHI) program.There were no statistically significant differences in age or
sex distribution between the patients in the sample group
and the original population approved by NHRI.
We used the data from all individuals with claims be-
tween January 1997 and December 2007. This study was
approved by the Institutional Review Board of the Far
Eastern Memorial Hospital (IRB No. 101013-E), New Taipei,
Taiwan.
Study design
A retrospective cohort study was designed in our study. Our
study sample consisted of all patients with ambulatory care
visits for CKD between January 1997 and December 2002
(nZ 23,734) who matched any of the principal diagnoses of
the International Classification of Diseases, Ninth Revision
(ICD-9-CM) code of CKD. We defined patients with CKD as
those in whom an event was diagnosed that was described
under chronic glomerulonephritis (ICD-9-CM codes 582.9,
582.1, 582.4, 582.21), chronic pyelonephritis (590.00),
chronic renal failure (585), diabetes mellitus with ne-
phropathy (583.81 ), immunoglobulin (Ig)A or IgM nephritis
(583.589), nephritis and nephropathy (583.9), nephrotic
syndrome (581.x), and renal failure (586).
Study sample
We limited the study sample to the CKD population,
excluding patients with fewer than three visits with the
diagnosis of CKD and in whom CKD had been diagnosed prior
to 1997. We selected only the first ambulatory care visits
for newly diagnosed CKD in this cohort database since 1997
and the patients that had more than three visits during the
study period. Classification study groups including deter-
mination of PPI and non-PPI groups. We excluded patients
who had received a prescription for any PPIs prior to the
study.
ICD-9 code of diagnosis (variables of interest)
The primary objective of this study was to observe whether
patients with CKD receiving PPIs developed pneumonia or
not. Patients included those who had any inpatient diag-
nosis of a type of pneumonia with an ICD-9-CM code 481,
392 C.-H. Chen et al.482, 483, 485, and 486 between January 1998 and
December 2008. These codes have been used by other
studies.12,13 In addition, we use the appearance of pneu-
monia as an outcome measure.
The ICD-9-CM of the diagnoses of comorbidities were
cerebrovascular disease (CVA, 430-438), acute renal failure
(584), ischemic heart disease (414.9), chronic obstructive
pulmonary diseases (COPD, 496), asthma (493), and dia-
betes mellitus (250). The covariate information was
collected at the time the patient entered the cohort.
Incidence rates of pneumonia were calculated for exposed
and unexposed individuals.
PPI classification and database codes
Five PPIs are currently available, including omeprazole,
esomeprazole, lansoprazole, pantoprazole, and rabepra-
zole. We included both intravenous and oral drugs in this
study. To avoid underestimation of some patients using
more than one kind of PPIs, we selected total drug use
number (except lansoprazole because no data were avail-
able in the study period) and patient number from the
database. Drugs were classified according to the anatomic
therapeutic chemical system developed for the NHI
Research Database (NHIRD) drug utilization program. We
used a defined daily dose (DDD) recommended by the World
Health Organization (WHO) for measuring drug utilization.14
Each patient was individually tracked for 5 years,
starting from his or her initial outpatient visit, to identify
those who had developed pneumonia during the follow-up
period. To calculate the number of patients with CKD who
developed pneumonia during the 5-year period after their
first outpatient visits, the data were also linked to the PPI
drug use data in the NHIRD in Taiwan.
Cohort setting
Patients were eligible for inclusion if they received any PPI
treatment between January 1998 and December 2002 and if
pneumonia had been diagnosed. The date of the first
diagnosis of CKD since January 1997 was used to determine
the case group. A patient was recruited into our study group
when three CKD diagnoses were collected. PPI prescriptions
after the last date of three CKD diagnoses were collected to
decide if the patient was in the PPI or non-PPI group. The
patient was followed up until the development of pneu-
monia or up to 5 years in our study. If the patient has no
pneumonia after 5 years of follow-up, he or she was
considered censored. The cumulative incidence rate of
pneumonia was estimated during the follow-up period, a
maximum of 5 years. The exclusion criteria were used:
previous diagnosis of CKD, any PPI use, or a diagnosis of
pneumonia in the year preceding the cohort entry date.
Statistical analysis
The SAS version 9.1 statistical package (SAS Institute Inc.,
Cary, NC, USA) was used to perform all analyses in this
study. The t-test and Pearson c 2 test were used to examine
the differences in demographic characteristics (age, sex)
and potential confounders, including CVA, acute renalfailure, ischemic heart diseases, COPD, asthma, and dia-
betes mellitus between patients either receiving or not
receiving PPI therapy during the follow-up period.
We calculated the incidence of pneumonia during the 5-
year follow-up period and examined the differences in the
risk of pneumonia between the two groups. Multivariate
logistic regressions were performed to estimate the hazard
ratio (HR) of pneumonia occurring in the study and com-
parison groups. We also adjusted the potential confounder
including age, sex, CVA, acute renal failure, ischemic heart
diseases, COPD, asthma, and diabetes mellitus for the risk
of development of pneumonia. The differences were
established as statistically significant if a two-sided
p  0.05. Occurence of pneumonia was assessed using
KaplaneMeier analysis, with significance based on the log-
rank test.Results
We identified a total of 8,076 patients with CKD in this study
cohort (Fig. 1). Among the 277 patients receiving PPIs, 53
(19.1%) had received a diagnosis of pneumonia. Of the
7,799 patients who did not receive PPIs, 566 (7.3%) had
received a diagnosis of pneumonia (Table 1). The mean age
of patients in the PPI exposure group was higher than that
of the non-PPI exposure group (63.34  13.03 vs.
54.2  18.31, p < 0.001). In the PPI group, patients
appeared more likely to have several pre-existing illnesses
such as ischemic heart diseases, asthma, and diabetes
mellitus (p < 0.001) than in the non-PPI group (Table 1).
Using multivariate analysis, we adjusted all of the potential
confounders between the two groups, including older age,
sex, and the comorbidities. Table 2 shows the crude and
adjusted HR to develop pneumonia. We stratified the pa-
tients’ age into four groups and found that patients <20
years and >40 years had the risk of pneumonia. However,
after adjusting the HR, older age groups (>60 years) had a
high risk for pneumonia [adjusted HR: 1.06 (95%
CI Z 1.05e1.08)]. In this study, older patients with co-
morbid illness such as CVA, COPD, asthma, and diabetes
mellitus had a high risk for pneumonia.
Although there are five PPIs currently available in
Taiwan (omeprazole, esomeprazole, lansoprazole, pan-
toprazole, and rabeprazole), no data on lansoprazole
exposure could be found in this study. Table 3 shows the
risk of pneumonia with exposure to different PPIs. Among
patients with CKD, those receiving esomeprazole, omep-
razole, and rabeprazole had a higher incidence of pneu-
monia than those receiving pantoprazole. Based on the
DDD, there was no significant difference in dose effect
analysis in 30e60 DDD compared with the duration of PPI
exposure. We observed that the risk of pneumonia in <30
DDD was 21.2% (HR: 3.44, 95% CIZ 2.25e5.26) and the risk
of pneumonia in >90 DDD was 25% (HR: 4.26, 95%
CI Z 1.64e9.85; Table 4).
Fig. 2 demonstrates KaplaneMeier curves of the occur-
rence of pneumonia in patients with CKD receiving PPI
treatment. The cumulative incidence of pneumonia was
higher in the PPI exposure group than in the non-PPI
exposure group throughout the 5-year follow-up period.
The difference is significant by log-rank test.
Figure 1. Flow chart of enrolled subjects from National Health Insurance Research Database of Taiwan. CKD Z chronic kidney
disease; PPI Z proton pump inhibitor.
Pneumonia risk with PPI in CKD patients 393Discussion
In this large population-based study, we observed that PPI
administration was strongly associated with the risk of
pneumonia in CKD patients. Among the 277 patients
receiving PPIs, pneumonia had been diagnosed in 53Table 1 Comparisons of demographic characteristics of patient
proton pump inhibitor in Taiwan, 1998e2002 (n Z 8,076)
Category Patients receiving
PPI
(n Z 277)
No. (%)
Occurrence of pneumonia 53 (19.1)
Age (mean  SD) 63.34  13.03
Sex (male) 174 (62.82)
CVA 59 (21.29)
Acute renal failure 2 (0.72)
IHD 73 (26.35)
COPD 83 (29.96)
Asthma 71 (25.63)
Diabetes mellitus 86 (31.04)
Mean time of pneumonia (days) 954  576
COPD Z chronic obstructive pulmonary disease; CVA Z cerebrovasc
inhibitor; SD Z standard deviation.(19.1%). Although some previous studies presented similar
results, this is the first study to focus on patients with
CKD.2e4
CKD not only reflects target organ injury and systemic
vascular disease in the general population but is also
recognized as resulting in a high risk of GERD, peptic ulcer,s with chronic kidney disease with receiving and not receiving
Patients not receiving
PPI
(n Z 7,799)
p
No. (%)
566 (7.3) <0.001
54.20  18.31 <0.001
4090 (52.44) <0.001
1107 (14.19) <0.001
43 (0.55) 0.71
1075 (0.14) <0.001
1289 (16.53) <0.001
1229 (15.73) <0.001
1414 (18.13) <0.001
1544  397 <0.001
ular disease; IHD Z ischemic heart disease; PPI Z proton pump
Table 2 Crude hazard ratio and multivariate logistic regression-adjusted hazard ratio of patients with chronic kidney disease
receiving proton pump inhibitor and developing pneumonia, with respect to different confounders (n Z 277)
Variables Risk of pneumonia
Crude HR
(95% CI)
p Adjusted HR
(95% CI)
p
PPI 3.02 (2.21e4.12) <0.001 2.28 (1.64e3.15) <0.001
Age (mean  SD) 1.03 (1.03e1.04) <0.001 1.01 (1.01e1.02) <0.001
20 0.88 (0.83e0.94) <0.001 0.92 (0.86e0.99) 0.03
21e40 1.01 (0.96e1.07) 0.64 1.01 (0.95e1.06) 0.95
41e60 1.05 (1.02e1.09) <0.001 1.02 (0.98e1.05) 0.39
61 1.07 (1.05e1.09) <0.001 1.06 (1.05e1.08) <0.001
Sex (male) 1.19 (1.02e1.41) 0.03 1.05 (0.89e1.26) 0.55
CVA 3.06 (2.56e3.68) <0.001 1.86 (1.52e2.27) <0.001
COPD 2.89 (1.75e2.58) <0.001 1.72 (1.39e2.11) <0.001
Diabetes mellitus 2.29 (1.92e2.74) <0.001 1.56 (1.29e1.89) 0.01
IHD 2.13 (1.75e2.58) <0.001 1.13 (0.91e1.39) 0.27
Asthma 1.91 (1.58e2.31) <0.001 1.34 (1.09e1.65) 0.01
Acute renal failure 1.86 (0.78e4.41) 0.16 1.50 (0.62e3.66) 0.37
Adjusted for age, sex, CVA, acute renal failure, IHD, COPD, asthma, and diabetes mellitus.
CI Z confidence interval; COPD Z chronic obstructive pulmonary disease; CVA Z cerebrovascular disease; HR Z hazard ratio;
IHD Z ischemic heart disease; SD Z standard deviation.
394 C.-H. Chen et al.and upper gastrointestinal (GI) bleeding, especially in pa-
tients with ESRD.10,11 Therefore, caution should be exer-
cised in the use of PPIs for such patients.
Since omeprazole was first launched in 1988, PPIs have
become one of the most widely prescribed class of drugs
currently on the market.15 PPIs are able to increase gastric
pH and decrease gastric volume by inhibiting Hþ/Kþ aden-
osine triphosphatase, thus allowing bacterial colonization
and overgrowth in the upper GI tract.16,17 Thorens et al16
found that most bacteria species that overgrew in the
upper GI tract were similar to the bacteria colonizing the
oral cavity and the pharynx. These microorganisms of
oropharyngeal flora are strongly associated with the path-
ogens for patients with pneumonia receiving PPI therapy.
We did not analyze the pathogens of pneumonia in this
study due to the lack of availability of bacteria culture data
in the LHID database. However, a recent report from TheTable 3 Comparison of patients with chronic kidney dis-
ease and pneumonia receiving different proton pump in-
hibitors in Taiwan, 1998e2002 (n Z 277)
Proton pump inhibitora No. Patients with
pneumonia
No. %
Rabeprazole 53 12 36.36
Omeprazole 112 29 25.89
Esomeprazole 123 15 22.64
Pantoprazole 11 4 12.19
Total patients 277 53 19.13
a A few patients had more than one type of proton pump
inhibitor use.Netherlands showed that the pneumonia pathogens regar-
ded as oropharyngeal flora (e.g., Streptococcus pneumo-
niae) were more commonly found in PPI users than in non-
PPI users, whereas pathogens regarded as airborne or res-
piratory droplets (e.g., Coxiella burnetii) were less
frequently found in PPI users than in non-PPI users.18
In this study, we found that patients receiving esome-
prazole, omeprazole, and rabeprazole had a higher inci-
dence of pneumonia than those receiving pantoprazole.
This study is consistent with findings by Kirchheiner et al19
showing that pantoprazole is less effective in lowering pH.
For rabeprazole, the prevalence is 0.65% for patients with
pneumonia and 0.09% for patients without pneumonia. The
risk ratio of rabeprazole is even higher than other PPIs. The
reason might be that rabeprazole as well as esomeprazole
could achieve more rapid acid inhibition than other PPIs.20
Therefore, repeated administration of PPIs would consid-
erably delay gastric emptying and increase the risk of
pneumonia caused by profound irreversible gastric acid
suppression.21
Previous studies shows PPI use increases the risk of
pneumonia in children and adults.22 In our study, we found
that patients older than 60 years with comorbid illness such
as CVA, COPD, asthma, and diabetes mellitus had a high risk
for pneumonia. This finding is compatible with another
study.2 It is difficult to explain because these comorbidities
have repeatedly been associated with pneumonia with or
without PPI administration. However, patients with COPD
always had a high prevalence rate of GERD or peptic ulcer,
especially in those who smoke.18 PPIs cause few adverse
effects with short-term use. However, it has been associ-
ated with an increased risk of pneumonia and other in-
fections with long-term administration of PPIs.23
As for the dose and duration use, there was no significant
difference in dose effect analysis in 30e60 DDD compared
with the duration of PPI exposure. However, we observed
Table 4 Dose effect analysis of patients with chronic kidney disease who received proton pump inhibitor therapya
Patients with CKD and PPI exposure(n Z 277)
<30 DDD 30e60 DDD 61e90 DDD >90 DDD
(n Z 132) (n Z 82) (n Z 31) (n Z 32)
Pneumonia, n (%) 28 (21.21) 11 (13.41) 6 (19.35) 8 (25)
Crude HR 3.44** 1.98 3.07* 4.26**
(95% CI) 2.25e5.26 0.94e3.79 1.03e7.51 1.64e9.85
Adjusted HR 3.32** 1.97 2.94* 4.34**
(95% CI) 2.16e5.05 0.99e3.73 1.19e7.23 1.94e9.72
a The hazard ratios were adjusted for age, sex, cerebrovascular disease, acute renal failure, ischemia heart disease, chronic
obstructive pulmonary disease, asthma, diabetes mellitus.
* p < 0.05.
** p < 0.001.
CI Z confidence interval; CKD Z chronic kidney disease; DDD Z defined daily dose; HR Z hazard ratio; PPI Z proton pump inhibitor.
Pneumonia risk with PPI in CKD patients 395that patients receiving PPIs for <30 DDD or >90 DDD had a
high risk of developing pneumonia. These interesting re-
sults were partly inconsistent with those of Sarkar et al,24
who found that PPI therapy within 30 days was associated
with an increased risk of pneumonia and were not associ-
ated with longer-term use of PPIs. Gulmez et al3 also found
that the highest odds ratio (OR) for PPI therapy started 0e7
days prior to the index date (OR, 5.0; 95% CI 2.1e11.7).
After a longer term (> 84 days) of PPI therapy, OR
decreased to 1.3 (95% CI, 1.2e1.4).
Nevertheless, there were some limitations in this study.
First, we could not measure the drugs not claimed to the
NHI because the NIHD was a secondary database. In Taiwan,
PPIs could be claimed to the NIH only for the patients
receiving endoscopic examination with a positive result of
GERD or peptic ulcer. A large proportion of patients who
refused endoscopic examination and bought PPIs by them-
selves from the local pharmacy could not be estimated.
Second, we could not obtain the laboratory results or re-
ports of radiographic findings of pneumonia from the
claimed data from the NIHD.Figure 2. KaplaneMeier curves of the occurrence of pneu-
monia in patients with chronic kidney disease. PPI Z proton
pump inhibitor.In conclusion, the patients with CKD and PPI usage had a
higher rate of pneumonia in comparison with those not
using PPIs throughout the follow-up period. Therefore, PPI
usage is a potential risk factor of pneumonia in patients
with CKD. Although PPIs are indicated for use in patients
with CKD, physicians should pay careful attention when
prescribing PPIs for these patients.Acknowledgments
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